I-Bridge Capital, a health-care focused venture capital firm and incubator based in Shanghai, has announced the establishment of a joint venture with BioLineRx Ltd., a drug company based in Israel.
The venture will incubate healthcare startups, in order to develop innovative clinical and pre-clinical therapeutic projects. Though these projects will originate primarily in Israel, they will serve the Chinese healthcare market, as well as the global healthcare market.
I-Bridge Capital and BioLineRx will each provide 1 million USD in seed capital to the venture. BioLineRx will be responsible for identifying promising early-stage drugs that would suit the needs of Chinese consumers, which would then be in-licensed by iPharma for commercialization in China and beyond.
Dr. Jimmy Wei, Managing Partner and founder of I-Bridge Capital, remarked “The market in China is large and fast-growing, but it lacks innovative therapeutic assets and capabilities which address the increasing demands of our rapidly aging population.”
His comments highlight the main reason that Chinese investors are currently showing a keen interest in healthcare ventures overseas: the ability to fund and benefit from innovative healthcare technology and developments.
Chinese investors who are planning to make significant deployments in the global healthcare market often turn to trusted facilitators to source high-potential opportunities. Naseba has spent over a decade building close relationships with investors around the world, including China. Our analysts conduct daily phone calls with Chinese investors, and fully understand their needs and mandates.
On December 7th, 2016, in Shanghai, Naseba will be hosting the Chinese Healthcare Investment Meeting to introduce pre-screened Chinese investors to pre-qualified healthcare investment opportunities from around the world.
Submit your business case:
Oops! We could not locate your form.
To learn more, contact:
Naseba investor introduction
+971 4 455 7954